

Name **GIANNI DAL NEGRO**

## WORK EXPERIENCE

- Dates
- Position held
- Main activities and responsibilities

### **From January 2016**

Director Complex In Vitro Platforms

- Working in a matrix, deliver and implement a coordinated, integrated enterprise strategy for sustained growth in GSK's R&D application of complex human-relevant and translational in vitro models.
- Facilitate stakeholders' access to innovative human-relevant in vitro technologies by enabling connection with external experts and key opinion leaders.
- Spread a translational thinking culture by engaging scientists in pro-active dialogue to build inter-disciplinary bridges and a pre-clinical to clinical line of sight across GSK and external partners such that complex in vitro models are developed and used in the context of project teams' broader translational strategy

- Dates
- Position held
- Main activities and responsibilities

### **From June 2009 – to December 2010**

Director Non-animal Opportunities (former World-wide Director 3Rs)

- Represents the commitment of GSK in finding, validating and implementing 3Rs-oriented approaches and principles in animal research throughout the global organization.
- Accountable for implementation and management of the global GSK 3Rs plan.
- Represent GSK in international committees and initiatives relevant to the 3Rs (science, legislation, regulatory requirements)

- Dates
- Position held
- Main activities and responsibilities

### **From November 2003 – to May 2009**

Head of Investigative Toxicology, GlaxoSmithKline S.p.A., Verona

- Accountable for Investigative Toxicology activities complementing regulatory toxicology studies
- SA project team member:
  - Responsible for Safety Assessment activities on part of GSK portfolio, represents Safety Assessment at relevant inter-disciplinary project review meetings
- SA WW 3Rs reference person
  - Ensures knowledge and culture sharing in the 3Rs field within Safety Assessment and across other Pre-Clinical Development disciplines

- Dates
- Position held

### **From April 2001 – to November 2003**

Head of Cellular and Biochemical Pathology, GlaxoSmithKline S.p.A., Verona.

Main activities and responsibilities

- Accountable for Clinical Pathology and In Vitro Toxicology Units in support of toxicological studies.

- Dates
- Position held

**From 1998 – to 2001**

Head of Clinical Pathology Laboratories and Responsible for *In Vitro* Toxicology, GlaxoWellcome S.p.A.

- Dates
- Position held

**From 1991-to 1998**

Head of Clinical Pathology Laboratories and Veterinary Responsible for Animal facilities, GlaxoWellcome S.p.A.

- Dates
- Position held

**From 1986-to 1991**

Coordinator of the Animal Models Laboratory, Microbiology Department, Glaxo S.p.A.

- Dates
- Position held

**From 1984-to 1986**

Veterinary Practitioner

**EDUCATION AND TRAINING**

- Date
- Name and type of organisation providing education and training
- Title of qualification awarded

**28-June-1984**

University of Parma, Italy – Faculty of Veterinary Medicine

Doctor of Veterinary Medicine

**MOTHER TONGUE**

Italian

**OTHER LANGUAGES**

- Reading skills
- Writing skills
- Verbal skills

**English**

Excellent  
Excellent  
Excellent

**SPECIAL ACHIEVEMENTS:**

- From March 2017, Member of the EUROTOX Registration Sub-committee managing the European Register of Toxicologists
- From January to December 2016, Chair of the European Partnership for Alternative Approaches to Animal Testing (EPAA)
- Outstanding Reviewer 2015 Elsevier Award (Journal Toxicology In Vitro)
- From 2015, contract Professor at the University of Ferrara, Faculty of Biology
- From 2015, peer reviewer of the journal Clinical and Experimental Dermatology
- From March 2014, member of the Royal College of Veterinary Surgeons
- From January to December 2011, chair of the European Partnership on Alternative to Animal Testing (EPAA) Industry Steering Committee
- Starting from June 2010, member of the Editorial Board of the journal Toxicology In Vitro (Elsevier)
- From 2010, member of the EFPIA Pre-Clinical Development Committee

- From February 2008 to May 2009, member of the ECVAM Scientific Advisory Committee (ESAC) as the EFPIA (European Federation of Pharmaceutical Industries and Associations) representative
- From 2009, European Registered Toxicologist
- From May 2007 to October 2012, President of the Italian Association for Laboratory Animal Science (AISAL)
- Member of the Scientific Committee of the 10<sup>th</sup> Federation of European Laboratory Animal Science Associations (FELASA) and the XIV International Council for Laboratory Animal Science (ICLAS) Joint Meeting Cernobbio (CO) Italy - June, 11-14 2007
- From 2006, member of the EPAA Working Groups 2 and 5
- Member of the management team for the ECVAM project "Pre-validation of rat CFU-GM" (2006)
- Member of an independent scientific expert panel to review the validation status of in vitro acute toxicity test methods to evaluate acute toxicity (NIH, Bethesda, Maryland, 22-24 May 2006)
- Guest Editor of a special issue of the journal *Toxicology In Vitro* (2006)
- From 2005, contract Professor of Investigative Toxicology at the University of Bologna, Faculty of Pharmacy.
- Reviewer for the journal *Toxicology In Vitro* and for the journal *Current Pharmaceutical Design*
- Invited lecture on In Vitro Methods in Research within the course for the FELASA accreditation cat. C (University of Milan, Veterinary Faculty, 17 October 2003)
- Invited as Farmindustria (Italian Association of Pharmaceutical Industries) representative to participate to workshops on "Animal Use in Scientific Research: Modification of the Decree 116/1992", (Roma, Chamber of Deputies, years 2003-2004).
- Invited participant to the ECVAM Workshop on Strategies to Replace In Vivo Acute Systemic Toxicity Testing (Ispra, 15-18 September 2003)

## PUBLICATIONS

1. Cristofori P, Dal Negro G, Terron A, Dorigatti R (1992). Determination of protein concentration in urine by two different methods and their applicability in toxicity studies *Toxicology letters* **61** (Suppl 1).
2. Dal Negro G, Cristofori P, Spagnolo D, Tarter G, Pastorino A, Micheli D, Magro A, Bonato M, Terron A. The fat-fed hamster as a model of atherosclerosis (poster) 5th Congress of International Society of Animal Clinical Biochemistry. Parma, 2-6.9.1992.
3. Dal Negro G, Cristofori P, Raimondo S Interference of repeated small blood withdrawals with the haematological parameters in young rats (oral communication). *5th Congress of International Society of Animal Clinical Biochemistry*. Parma, 2-6.9.1992.
4. Cristofori P, Micheli D, Lanzoni A, Spagnolo D, Dal Negro G, Pastorino AM, Tarter G, Ratti E, Gaviraghi G, Sbarbati A. Antiatherosclerotic activity of Lacidipine in hyperlipidemic Hamster. *6th International Symposium: Pharmacological Control of Calcium and Potassium Homeostasis - Biological, Therapeutical and Clinical Aspects*, Florence, 4-6.10.1994.
5. Airaghi R, Berlingozzi S, Cannata S, Dal Negro G, Melloni E, Motta F (1994). Routine laboratory analysis for preclinical research in the pharmaceutical industry in Italy: an overview. *Comparative Haematology International* **4**: 136-142.
6. Weingand K, Brown G, Hall R, Davies D, Gossett K, Neptun D, Waner T, Matsuzawa T, Salemink P, Froelke W, Provost JP, Dal Negro G, Batchelor J, Nomura M, Groetsch H, Boink A, Kimball J, Woodman D, York M, Fabianson-Johnson E, Lupart M, Melloni E (1996). Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. *Fundamental & Applied Toxicology*. **29**(2): 198-201.
7. Dal Negro G, Cristofori P (1996). A new approach for evaluation of in vitro haemolytic potential. *Comparative Haematology International*. **6** (1): 35-41. Presented at the Second European Conference on Comparative Clinical Pathology, 13-16 June, Dijon, France.

8. Dal Negro G, Cristofori P, Casartelli A, Bonato M. The Kidney Slice Model: Reappraisal of this Method as an Useful Tool for the Early Assessment of Nephrotoxicity Potential of a New Medicine. *III Congresso Nazionale di CELLTOX*, Vietri sul Mare (SA), 5-7 November 1997.
9. Sartor F and Dal Negro G (1998). In Vitro Dynamic Model to Evaluate Precipitation upon Injection. *European Journal of Pharmaceutical Sciences*. **6** (Suppl 1): S7.
10. Dal Negro G, Magro A, Terron A, Bonato M, Cristofori P (1999). In Vitro Safety Evaluation of Potential Haemolytic Surface active Injectable Drugs. *European Journal of Pharmaceutical Sciences*. **6** (Suppl 1): S7. Presented at the 3<sup>rd</sup> World Congress on Alternatives and Animal Use in the Life Science, 29.08-02.09.99, Bologna, Italy.
11. Dal Negro G, Casartelli A, Munaro S, Paschetto S, Cristofori P. In Vitro approaches for the Assessment of the Toxic Potential of New Medicines in Pharmaceuticals Research (oral communication). *The Fourth European Comparative Pathology Meeting*, June 01-04 1999, Verona, Italy. Dal Negro G, Magro A, Terron A, Bonato M and Cristofori P (1999). In Vitro Safety evaluation of Potential Haemolytic Surface Active Injectable Drugs. *ATLA*. **27**: 120.
12. Dal Negro G, Munaro S, Casartelli A, Cristofori P Evaluation of the Hepatotoxic Potential of New Drugs with the Primary Hepatocyte Monolayer Model. *XII Congresso Nazionale della Societa` Italiana di Tossicologia*, 23-26 February 2000, Bologna, Italy.
13. Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, Cristofori P, Dal Negro G, Marchiori P, Gaviraghi G, Falconi M, Pederzoli P, Zamboni G, Scarpa A (2001). Successful Xenografting of Cryopreserved Primary Pancreatic Cancers. *Virchows Arch*. **438**: 154-158.
14. Dal Negro G, Bonato M, Gribaldo L (2001). In Vitro Bone Marrow Granulocyte-macrophage Progenitor Cultures in the Assessment of Hematotoxic Potential of the New Drugs. *Cell Biology and Toxicology* **17** (2): 95-105.
15. Marcucci S, Bonora S, Falconi M, Sorio C, Orlandini S, Beghelli S, Cristofori P, Dal Negro G, Marchiori PN, Bassi C, Scarpa A, Pederzoli P (2002). Progetto Integrato per la Ricerca Translazionale nel Carcinoma Duttale del Pancreas. *Chirurgia Italiana* **54** (6): 845-854.
16. Casartelli A, Bonato M, Cristofori P, Crivellente F, Dal Negro G, Masotto I, Mutinelli C, Walko K and Bonfante V (2003). A Cell-based Approach for the Early Assessment of the Phospholipidogenic Potential in Pharmaceutical Research and Drug development. *Cell Biology and Toxicology* **19**(3): 161-176.
17. Zucco F, Batto AF, Bises G, Chambaz J, Chiusolo A, Consalvo R, Cross HS, Dal Negro G, De Angelis I, Fabre G, Guillou F, Hoffmann S, Laplanche L, Morel E, Pinçon-Raymond M, Prieto P, Turco L, Ranaldi G, Rousset M, Sambuy Y, Scarino ML, Torreilles F and Stammati L (2005). Optimisation of Protocols for the Maintenance and Characterization of Human Intestinal Caco-2 Cells: an Interlaboratory Study. *ATLA* **33**(6): 603-18.
18. Gennari A, Van den Berghe C, Casati S, Castell J, Clemenson C, Coecke S, Colombo A, Curren R, Dal Negro G, Goldberg A, Gosmore C, Hartung T, Langezaal I, Lessigiarska I, Maas W, Mangelsdorf I, Parchment R, Prieto P, Riego Sintes J, Ryan M, Schmuck G, Stitzel K, Stokes W, Vericat JA and Gribaldo L (2004) Strategies to Replace In Vivo Acute Systemic Toxicity Testing. *ATLA* **32**: 437-459.
19. Dal Negro G, Vandin L, Bonato M, Sciuscio D (2006) Toward Refinement of the Colony-forming Unit-granulocyte/macrophage Clonogenic Assay: Inclusion of a Metabolic System. *Toxicology In Vitro* **20**: 743-749.
20. Dal Negro G, Vandin L, Bonato M, Repeto P, Sciuscio D (2006) A New Experimental Protocol as an Alternative to the Colony-forming Unit-granulocyte/macrophage (CFU-GM) Clonogenic Assay to Assess the Haematotoxic Potential of New Drugs. *Toxicology In Vitro* **20**: 750-756.
21. Kimber I., Humphris C., Westmoreland C., Alepee N., Dal Negro G. And Manou I. (2011) Computational chemistry, systems biology and toxicology. Harnessing the chemistry of life: revolutionizing toxicology. A commentary *Journal of Applied Toxicology* **31**: 206–209.
22. Simon E. Ward, Mark Harries, Laura Aldegheri, Nigel E. Austin, Stuart Ballantine, Elisa Ballini, Daniel M. Bradley, Benjamin D. Bax, Brian P. Clarke, Andrew J. Harris, Stephen A. Harrison, Rosemary A. Melarange, Claudette Mookherjee, Julie Mosley, Gianni Dal Negro, Beatrice Oliosi, Kathrine J. Smith, Kevin M. Thewlis, Patrick M. Woollard, and Shahnaz P. Yusuf (2011) Integration of Lead Optimization with Crystallography for a Membrane-Bound Ion Channel Target: Discovery of a New Class of AMPA Receptor Positive Allosteric Modulators. *Journal of Medicinal Chemistry* **54**(1): 78-94.

23. Kinsner-Ovaskainen A., Maxwell G., Kreysa J., Barroso J., Adriaens E., Alépée N., Berg N., Bremer S., Coecke S., Comenges J.Z., Corvi R., Casati S., Dal Negro G., Marrec-Fairley M., Griesinger C., Halder M., Heisler E., Hirmann D., Kleensang A., Kopp-Schneider A., Lapenna S., Munn S., Prieto P., Schechtman L., Schultz T., Vidal J., Worth A. and Zuang V. (2012) Report of the EPAA–ECVAM Workshop on the Validation of Integrated Testing Strategies (ITS). *ATLA* **40**(3): 175-181.
24. Caloni F., Costa P., Dal Negro G., De Angelis I., Lazzari G., Matteucci G., and Vitale A. (2012) Practical Aspects in the Application of the New Legislation: Alternative Methods and 3R Principle, Role of Ethical Committees and Animal Suffering. *ALTEX* **29**(4): 437-443.
25. F. Caloni, P. Costa, G. Dal Negro, I. De Angelis, S. Dotti, G. Lazzari, G. Matteucci, and A. Vitale Alternative Methods: 3Rs, Research and Regulatory Aspects, *ALTEX* 30, 3/13, 2013, 378-379. ISSN: 1868-596X (IF: 3.63)
26. F. Caloni, G. Dal Negro, P. Costa, S. Dotti, G. Matteucci, A. Vitale, I. De Angelis 3Rs and new frontiers in laboratory techniques *ALTEX*, 31, 3, 2014, 367-368 ISSN: 1868-596X, doi: 10.14573/altex.1406182 (IF: 3.63)

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003

In fede,

Gianni Dal Negro